New scan could spot prostate cancer more accurately

NCT ID NCT07052214

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial is testing whether combining a special PET scan (PSMA PET) with MRI can detect prostate cancer better than standard methods. About 204 men with suspected prostate cancer will receive the combined imaging, and results will be compared to biopsy findings. The goal is to see if this approach improves accuracy and reduces unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

68Ga-PSMA-11 (Gallium Ga 68 Gozetotide)

What this could lead to

If successful, this could make prostate cancer detection more accurate, reducing unnecessary biopsies and catching cancers earlier.

What could go wrong

This is a Phase 3 trial, but it's still experimental. The new scan may not prove better than current methods, and false positives or negatives remain possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSMA-PET are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

choanal atresia prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Australian Prostate Centre

    RECRUITING

    Melbourne N., Victoria, 3055, Australia

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••